Cargando…

Safety comparison of additives in antiglaucoma prostaglandin (PG) analog ophthalmic formulations

PURPOSE: To investigate the safety of five types of antiglaucoma prostaglandin analog ophthalmic formulations, and to clarify their differences in accordance with contained additives (preservatives and surface-active agents). METHODS: The following five types of ophthalmic solutions and three types...

Descripción completa

Detalles Bibliográficos
Autores principales: Fukuda, Masamichi, Shibata, Shinsuke, Shibata, Naoko, Hagihara, Kenta, Yaguchi, Hiromoto, Osada, Hiromi, Takahashi, Nobuo, Kubo, Eri, Sasaki, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3601024/
https://www.ncbi.nlm.nih.gov/pubmed/23515900
http://dx.doi.org/10.2147/OPTH.S40147
_version_ 1782475705248907264
author Fukuda, Masamichi
Shibata, Shinsuke
Shibata, Naoko
Hagihara, Kenta
Yaguchi, Hiromoto
Osada, Hiromi
Takahashi, Nobuo
Kubo, Eri
Sasaki, Hiroshi
author_facet Fukuda, Masamichi
Shibata, Shinsuke
Shibata, Naoko
Hagihara, Kenta
Yaguchi, Hiromoto
Osada, Hiromi
Takahashi, Nobuo
Kubo, Eri
Sasaki, Hiroshi
author_sort Fukuda, Masamichi
collection PubMed
description PURPOSE: To investigate the safety of five types of antiglaucoma prostaglandin analog ophthalmic formulations, and to clarify their differences in accordance with contained additives (preservatives and surface-active agents). METHODS: The following five types of ophthalmic solutions and three types of additives were investigated: latanoprost (Xalatan(®); latanoprost), tafluprost (Tapros(®); tafluprost), bimatoprost (Lumigan(®); bimatoprost), travoprost (Travatan(®); travoprost), travoprost (Travatan Z(®); travoprost-Z), benzalkonium chloride (BAK), polyoxyethylene hardening castor oil 40 (HCO-40), and polysorbate 80 (P-80). These experimental solutions were exposed to the cultured cells of a rabbit-derived corneal cell line for a certain time, and the exposure time causing 50% cell damage (CD50), indicated by the ratio of viable cells to total cells was calculated (in vitro). In addition, corneal resistance (CR) was measured and CR ratio (post-treatment CR/pretreatment CR × 100) was calculated (in vivo). RESULTS: CD50 of each ophthalmic solution was the longest with tafluprost, followed by travoprost-Z, bimatoprost, travoprost, and latanoprost. CD50 of 0.005%, 0.01%, and 0.02% BAK was 14.5 minutes, 8.1 minutes, and 4.0 minutes, respectively. The number of viable cells decreased to 60%, 8 minutes after exposure with HCO-40, and 30 minutes after being exposed to P-80. The CR ratio was 81.0% with travoprost and 82.0% with latanoprost, indicating a significant posttreatment reduction of CR (P < 0.05). The CR ratio did not decrease after treatment with tafluprost, travoprost-Z, or bimatoprost. The CR ratio of 0.005%, 0.01%, and 0.02% BAK was 105.0%, 90.5%, and 68.7%, respectively, and that of HCO-40 and P-80 was 108.7% and 114.2%, respectively. CONCLUSION: BAK, HCO-40, and P-80 were thought to be involved in corneal injuries caused by each ophthalmic solution. Corneal injuries due to surface action were observed when using HCO-40 and P-80. When HCO-40 was combined with BAK, it induced micellar BAK and reduced corneal injuries by BAK.
format Online
Article
Text
id pubmed-3601024
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-36010242013-03-19 Safety comparison of additives in antiglaucoma prostaglandin (PG) analog ophthalmic formulations Fukuda, Masamichi Shibata, Shinsuke Shibata, Naoko Hagihara, Kenta Yaguchi, Hiromoto Osada, Hiromi Takahashi, Nobuo Kubo, Eri Sasaki, Hiroshi Clin Ophthalmol Original Research PURPOSE: To investigate the safety of five types of antiglaucoma prostaglandin analog ophthalmic formulations, and to clarify their differences in accordance with contained additives (preservatives and surface-active agents). METHODS: The following five types of ophthalmic solutions and three types of additives were investigated: latanoprost (Xalatan(®); latanoprost), tafluprost (Tapros(®); tafluprost), bimatoprost (Lumigan(®); bimatoprost), travoprost (Travatan(®); travoprost), travoprost (Travatan Z(®); travoprost-Z), benzalkonium chloride (BAK), polyoxyethylene hardening castor oil 40 (HCO-40), and polysorbate 80 (P-80). These experimental solutions were exposed to the cultured cells of a rabbit-derived corneal cell line for a certain time, and the exposure time causing 50% cell damage (CD50), indicated by the ratio of viable cells to total cells was calculated (in vitro). In addition, corneal resistance (CR) was measured and CR ratio (post-treatment CR/pretreatment CR × 100) was calculated (in vivo). RESULTS: CD50 of each ophthalmic solution was the longest with tafluprost, followed by travoprost-Z, bimatoprost, travoprost, and latanoprost. CD50 of 0.005%, 0.01%, and 0.02% BAK was 14.5 minutes, 8.1 minutes, and 4.0 minutes, respectively. The number of viable cells decreased to 60%, 8 minutes after exposure with HCO-40, and 30 minutes after being exposed to P-80. The CR ratio was 81.0% with travoprost and 82.0% with latanoprost, indicating a significant posttreatment reduction of CR (P < 0.05). The CR ratio did not decrease after treatment with tafluprost, travoprost-Z, or bimatoprost. The CR ratio of 0.005%, 0.01%, and 0.02% BAK was 105.0%, 90.5%, and 68.7%, respectively, and that of HCO-40 and P-80 was 108.7% and 114.2%, respectively. CONCLUSION: BAK, HCO-40, and P-80 were thought to be involved in corneal injuries caused by each ophthalmic solution. Corneal injuries due to surface action were observed when using HCO-40 and P-80. When HCO-40 was combined with BAK, it induced micellar BAK and reduced corneal injuries by BAK. Dove Medical Press 2013 2013-03-12 /pmc/articles/PMC3601024/ /pubmed/23515900 http://dx.doi.org/10.2147/OPTH.S40147 Text en © 2013 Fukuda et al, publisher and licensee Dove Medical Press Ltd This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Original Research
Fukuda, Masamichi
Shibata, Shinsuke
Shibata, Naoko
Hagihara, Kenta
Yaguchi, Hiromoto
Osada, Hiromi
Takahashi, Nobuo
Kubo, Eri
Sasaki, Hiroshi
Safety comparison of additives in antiglaucoma prostaglandin (PG) analog ophthalmic formulations
title Safety comparison of additives in antiglaucoma prostaglandin (PG) analog ophthalmic formulations
title_full Safety comparison of additives in antiglaucoma prostaglandin (PG) analog ophthalmic formulations
title_fullStr Safety comparison of additives in antiglaucoma prostaglandin (PG) analog ophthalmic formulations
title_full_unstemmed Safety comparison of additives in antiglaucoma prostaglandin (PG) analog ophthalmic formulations
title_short Safety comparison of additives in antiglaucoma prostaglandin (PG) analog ophthalmic formulations
title_sort safety comparison of additives in antiglaucoma prostaglandin (pg) analog ophthalmic formulations
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3601024/
https://www.ncbi.nlm.nih.gov/pubmed/23515900
http://dx.doi.org/10.2147/OPTH.S40147
work_keys_str_mv AT fukudamasamichi safetycomparisonofadditivesinantiglaucomaprostaglandinpganalogophthalmicformulations
AT shibatashinsuke safetycomparisonofadditivesinantiglaucomaprostaglandinpganalogophthalmicformulations
AT shibatanaoko safetycomparisonofadditivesinantiglaucomaprostaglandinpganalogophthalmicformulations
AT hagiharakenta safetycomparisonofadditivesinantiglaucomaprostaglandinpganalogophthalmicformulations
AT yaguchihiromoto safetycomparisonofadditivesinantiglaucomaprostaglandinpganalogophthalmicformulations
AT osadahiromi safetycomparisonofadditivesinantiglaucomaprostaglandinpganalogophthalmicformulations
AT takahashinobuo safetycomparisonofadditivesinantiglaucomaprostaglandinpganalogophthalmicformulations
AT kuboeri safetycomparisonofadditivesinantiglaucomaprostaglandinpganalogophthalmicformulations
AT sasakihiroshi safetycomparisonofadditivesinantiglaucomaprostaglandinpganalogophthalmicformulations